Articles tagged with T Lymphocytes
Researchers found a way to reverse HIV's deadly longevity by targeting its chemical changes that keep reservoirs alive. An existing ant-parasite drug, miltefosine, inhibits the PI3K/Akt pathway, which enables macrophages to survive despite surrounding toxicity.
A research team at Weill Cornell Medical College identified two genes, Pbx-1 and Prep-1, that play a critical role in regulating interleukin-10 (IL-10) production. This discovery could lead to new avenues for understanding and treating diseases such as lupus, cancer, and HIV/AIDS.
Researchers designed a technique that uses the body's own cells and a virus to destroy cancer cells, which could lead to a new cancer vaccine. The study shows promising results in treating melanoma, lung cancer, and colorectal cancer by targeting tumor cells in the lymph nodes.
A research team led by Dr. Michael Starnbach is using genetically engineered mice to study the immune system's response to Chlamydia infections. They aim to understand which components of the immune system need to be stimulated to fight the infection, with the ultimate goal of developing a vaccine for adolescent girls.
A new study shows that immune cells battling chronic viral infections undergo changes that make them progressively less effective over time. Interventions, such as blocking the PD-1 pathway, can alleviate T-cell exhaustion and restore disease-fighting capability.
Chris Culbertson has received a 2007 Masao Horiba Award for his work on rapid analysis of individual T-lymphocyte cells using microfluidic devices. This honor recognizes the future potential and originality of his research, which could lead to unique measurement instruments.
Researchers detected viral genetic material in the placenta of a pregnant woman who died from bird flu. The study found that H5N1 virus can infect organs other than the lungs, including the brain, liver, and intestinal cells, in infected adults and fetuses.
Scientists discovered a key biochemical cycle that allows cancer cells to multiply unabated by suppressing the immune response. The research found that tryptophan is broken down into toxic kynurenines, starvng T-cells, which are then overwhelmed by an excess of kynurenine in the body fluids.
A recent study published in The Journal of Immunology found that SIV infection in monkeys does not always lead to AIDS, contradicting current thinking. Researchers propose that host/virus co-adaptation enables monkeys to limit T cell immune activation and apoptosis, a mechanism that contributes to disease progression.
Researchers found that reactive oxygen stimulates dendritic cells to up-regulate the immune antigen CD80, leading to T cell activation and increased TNF production. This causes excessive destruction of bone via osteoclasts.
Research in African monkeys reveals that CD4 T-cell depletion is one part of a complex scenario leading to AIDS. Studies suggest that immune function can be preserved despite significant loss of mucosal CD4 T-cells.
A recent study published in Immunity reveals that the presence of pro-death proteins Bax and Bak is necessary for healthy immune function, specifically in T-cell cells. The absence of these proteins disrupts calcium signaling pathways, leading to reduced energy production and impaired cell division.
Researchers found that Src inhibitors can target aggressive breast cancers, which lack estrogen receptors and are more prone to growth. By inhibiting the protein Src, these treatments show promise in improving patient outcomes.
Scientists at NIAID are exploring vaccines that reduce HIV levels, delay disease progression and prevent transmission. Early research suggests T-cell vaccines may have benefits, but questions remain about their effectiveness and potential side effects.
A glucosamine-like supplement called GlcNAc has been found to suppress the damaging autoimmune response seen in multiple sclerosis and type-1 diabetes mellitus. In studies on mice, GlcNAc inhibited the growth and function of abnormal T-cells that incorrectly direct the immune system.
Triple-negative breast cancer cells are sensitive to cisplatin, a common chemotherapeutic drug that can be effective in treating the disease. Researchers also found that delta-Np63 and TAp73 proteins play a crucial role in mediating chemosensitivity to cisplatin.
Researchers at UTMB overturned the long-held medical dogma on RSV, finding that an inadequate immune reaction is associated with severe infections. The study's findings have major implications for developing therapies and treating viral respiratory infections during infancy.
A Cornell researcher is working on a quick and affordable immune system test for people in the developing world. The test aims to help HIV/AIDS sufferers get proper treatment, potentially extending their lives by 10-15 years.
Scientists at UCLA's Jules Stein Eye Institute have discovered defects in the infection-fighting T-cells of Graves' disease (GD) patients' immune systems. The study found an abnormal surplus of receptors targeted by an antibody that mistakenly attacks the thyroid gland, causing inflammation and damage to eye tissue.
Carbon nanotubes successfully deliver RNA fragments that shut off genes for HIV-specific receptors on human T-cells. This approach significantly slows down HIV infection by blocking the virus's entry points.
Researchers identified primary targets of HIV-1 in the human vagina, finding that Langerhans cells and CD4+ T cells are key sites of entry. The study suggests that blocking transmission through the vaginal epithelium could prevent local spread and ultimately alleviate the pandemic.
Researchers at Yale University have developed a novel approach to synthesizing nanowires, allowing them to integrate with microelectronic systems and act as highly sensitive biomolecule detectors. This breakthrough has profound implications for the application of nanoscience technologies and future diagnostics.
Researchers at Princeton University have found a specific genetic trigger that can deactivate the HIV virus, potentially leading to new treatments. The trigger, involving an enzyme called SirT1, can keep the virus in its dormant phase, reducing its ability to replicate.
A study published in Nature Immunology reveals that lymph node cells instruct immune system cells to leave healthy tissue alone, protecting the small intestine from attack. This finding may lead to new forms of treatment for autoimmune diseases such as Type 1 diabetes and multiple sclerosis.
Researchers at St. Jude Children's Research Hospital found that harvesting aggressive stem cells from donated bone marrow can reduce the time it takes for a child's immune system to rebuild after a bone marrow transplant. This could lead to lower risk of fatal virus infections and improved long-term outcomes.
New research suggests that beta-agonist medications used in asthma treatment can increase type 2 T cell accumulation, potentially worsening related diseases. The study's findings highlight the need for anti-inflammatory corticosteroids in moderate to severe asthma treatment.
Researchers at the University of Pennsylvania School Medicine have successfully tested a new gene therapy vector that inhibits HIV replication. The treatment, called VRX496, has shown promising results in reducing viral loads and improving immune function in patients with chronic HIV infection.
Researchers have developed a new type of laboratory mouse with human-like immune systems, allowing for the study of human-pathogen interaction and development of disease therapies. The 'Bone Marrow Liver Thymic' mice can fight certain infections, including toxic shock syndrome and Epstein Barr virus.
A Hopkins study reveals that T lymphocytes, part of the immune system, play a dual role in organ damage after transplantation. While they produce toxic chemicals that contribute to IRI, they also appear to protect transplanted kidneys from damage. The findings could lead to new strategies for preventing or rapidly treating IRI.
Researchers found protein splicing occurs beyond RNA splicing, producing non-linear peptides and expanding antigenic options. This mechanism increases the number of potential antigens from a single protein, widening vaccine applicability against cancer and infectious diseases.
Researchers successfully transformed normal immune cells into tumor fighters, demonstrating their ability to persist in the body and shrink large tumors in humans. The engineered cells were found to show signs of persistence in 15 of the 17 patients in the study, with two patients seeing significant tumor shrinkage.
Researchers found that B cells expressing a special protein called DC-SIGN are necessary for HIV to infect T cells. Activating DC-SIGN on B cells allows HIV to invade T cells, highlighting a new target for future studies and drug development.
The study found that the efavirenz plus two-NRTI regimen was significantly more effective at reducing HIV viral load in the blood. A second approach, lopinavir/ritonavir, also performed well and may be a viable alternative for patients who experience intolerable side effects from NRTIs. The trial included 753 participants and showed su...
Researchers identify DC-SIGN on B cells as crucial for HIV's takeover of T cells, revealing a new pathway for antiviral drug development. About 8% of B cells express the protein, which allows HIV to invade T cells while sparing B cells.
University of Illinois researchers found unexpected two-way communication between blood stem cells and T cells, changing their fate. This loop may lead to a strong immune response, increasing the risk of graft-versus-host disease or rejection.
University of Rochester experts discuss how flu invades and responds to the body, with a focus on understanding its pathogenesis. The research aims to prevent potential modification of the flu virus for lethal use and develop more effective treatments.
OHSU researchers found that interleukin-15 (IL-15) restores tissue CD4+ T cells when given with antiretroviral drugs in SIV-infected monkeys. This discovery offers hope for effective therapies to boost HIV patients' immune systems.
The HBZ protein is crucial for persistent infection of HTLV-1 in an animal host. Researchers discovered that a drug targeting this protein could disrupt viral replication and provide a new therapy for infected individuals.
Researchers at Children's Hospital of Philadelphia developed a novel lab technique to manipulate human T cells using RNA interference, overcoming previous limitations. The approach successfully silenced genes in 'slippery' immune cells, opening potential avenues for treating HIV and other diseases.
Researchers at Ohio State University have discovered that a cancer virus protein is necessary for the virus to successfully infect and reproduce in the body. The protein, p13, plays a critical role in the early phase of infection, and its function could be targeted by new drugs or vaccines.
Researchers at Rice University propose a novel approach to combat Dengue virus by administering multiple vaccines simultaneously at different locations on the body, bypassing immunodominance and enhancing immunity against all four closely related viruses. This strategy has implications for other diseases such as HIV and cancer.
Researchers are testing rituximab to see if it can prevent the immune system from attacking the pancreas, a key component of insulin production. The study aims to reduce long-term complications associated with type 1 diabetes, such as heart disease and kidney damage.
Researchers have developed a strategy to overcome biological obstacles in cell therapy for cancer by stimulating tumor-reactive T cells with interleukin-15. This approach has shown promise in treating disseminated forms of leukemia in mice without damaging other tissues.
The study found that infant transplant patients resisted infections despite having low T cell counts, a crucial component in fighting viruses and cancer tumors. This discovery could lead to improved treatments for AIDS, cancers, and diseases of aging related to declining immune function.
Researchers have found that Sangamo's ZFN-modified cells are resistant to HIV infection, whereas control cells are infected. The treatment works by disrupting the CCR5 gene, a receptor required for HIV entry into immune cells. This approach has advantages over other drugs in development, which require constant antagonist presence.
Researchers at Johns Hopkins Medicine have identified a new therapeutic target for drugs to treat multiple sclerosis (MS) and other autoimmune diseases. By targeting dendritic cells, the researchers hope to stop faulty immune responses at an upstream level.
Researchers developed a technique to manipulate immunological synapses with molecular precision, revealing that spatial arrangement determines signal strength. This breakthrough may help develop treatments for autoimmune diseases and better understand cellular communication.
Research shows lead may cause additional long-term health problems, disrupting immune cells that fight off pathogens. An estimated 434,000 US children under age 5 have elevated lead levels in their blood.
The ATTACK project aims to engineer T-cells to target and destroy cancer tumors. By modifying the immune system's natural defense mechanisms, researchers hope to develop a selective treatment method that spares healthy cells.
Researchers developed a new approach to predict type 1 diabetes risk by combining older and newer methods, identifying a specific protein marker associated with rapid progression. The study found that individuals positive for this marker have an 80% risk of developing the disease after just 6.7 years.
A research team at the University of Montreal has developed a cancer-curing therapy using T-lymphocytes, which recognize and destroy abnormal cells. The treatment targets specific antigens found on cancer cells, producing interferon gamma and perforine/granzyme to eradicate tumors without causing side effects.
A recent study published in Nature Medicine reveals the importance of antigen-presenting cells in the graft-versus-leukemia effect, which occurs during bone marrow transplants. The discovery has significant implications for improving cellular immunotherapy and making it safer and more effective for cancer patients.
Researchers at McGill University Health Centre discovered that T lymphocytes, part of the body's defense mechanism, cause airway remodeling in asthmatics. This process leads to thickening of airway muscle and increased symptoms.
The largest study of unrelated bone marrow transplantation for leukemia has demonstrated similar survival rates for T-cell depletion and immunosuppressive drug therapy approaches. The study, published in The Lancet, also found no appreciable differences in cost or quality of life between the two methods.
Researchers have found a way to increase the potency of Khellinone, a naturally occurring substance with anti-inflammatory properties. By disrupting rogue T cell potassium channels, the compound reduces myelin damage and may help tackle multiple sclerosis.
Scientists discover how HIV protein fragment FP shuts down immune response in T cells. Researchers found that FP locks onto proteins involved in invoking large-scale immune response, effectively shutting them down.
Notch protein plays a crucial role in directing early T-cell development in the thymus, a small organ under the breastbone near the heart. This study provides new insights into the process, shedding light on how Notch signaling contributes to T-cell differentiation and potentially improving outcomes for transplant patients.
Patients with rheumatoid arthritis (RA) are at a higher risk of developing coronary artery disease (CAD), with more advanced atherosclerosis and increased cardiovascular death. The underlying RA disease process, particularly elevated CD4+CD28- T cells, contributes to this increased risk.
A study published in the Journal of Clinical Investigation shows that reinfusing anergic T cells into rhesus monkeys after kidney transplantation leads to prolonged and potentially indefinite graft survival without additional immunosuppressive agents. This approach has shown promise for improving organ transplantation outcomes in humans.
Researchers developed a vaccine targeting the local tumor environment to improve systemic anti-tumor immunity in melanoma patients. The study showed that the vaccine was safe and feasible, with partial responses and stable lesions observed in some patients.